{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:04:27Z","timestamp":1791525867457,"version":"4.3.4"},"reference-count":48,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The aims of this study were to measure the prevalence of polypharmacy and describe the prescribing of selected medications known for overuse in older people with polypharmacy in primary care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multinational retrospective cohort study across six countries: Belgium, France, Germany, Italy, Spain and the UK. We used anonymized longitudinal patient\u2010level information from general practice databases hosted by IQVIA. Patients \u226565\u2009years were included. Polypharmacy was defined as having 5\u20139 and \u226510 distinct drug classes (ATC Level 3) prescribed during a 6\u2010month period. Selected medications were: opioids, antipsychotics, proton pump inhibitors (PPI), benzodiazepines (ATC Level 5). We included country experts on the healthcare context to interpret findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Age and gender distribution was similar across the six countries (mean age 75\u201376\u2009years; 54\u201356% female). The prevalence of polypharmacy of 5\u20139 drugs was 22.8% (UK) to 58.3% (Germany); \u226510 drugs from 11.3% (UK) to 28.5% (Germany). In the polypharmacy population prescribed \u22655 drugs, opioid prescribing ranged from 11.5% (France) to 27.5% (Spain). Prescribing of PPI was highest with almost half of patients receiving a PPI, 42.3% (Germany) to 65.5% (Spain). Benzodiazepine prescribing showed a marked variation between countries, 2.7% (UK) to 34.9% (Spain). The healthcare context information explained possible underreporting for selected medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We have found a high prevalence of polypharmacy with more than half of the older population being prescribed \u22655 drugs in four of the six countries. Whilst polypharmacy may be appropriate in many patients, worryingly high usage of PPIs and benzodiazepines supports current efforts to improve polypharmacy management across Europe.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.16113","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T01:55:24Z","timestamp":1717034124000},"page":"2124-2136","source":"Crossref","is-referenced-by-count":49,"title":["The prevalence of polypharmacy in older Europeans: A multi\u2010national database study of general practitioner prescribing"],"prefix":"10.1111","volume":"90","author":[{"given":"Marion","family":"Bennie","sequence":"first","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom Public Health Scotland  Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yared","family":"Santa\u2010Ana\u2010Tellez","sequence":"additional","affiliation":[{"name":"Utrecht Centre for Pharmaceutical Policy &amp; Regulation, Utrecht Institute for Pharmaceutical Sciences (UIPS) Utrecht University  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1527-3274","authenticated-orcid":false,"given":"Githa Fungie","family":"Galistiani","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Universitas Muhammadiyah Purwokerto  Purwokerto Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Trehony","sequence":"additional","affiliation":[{"name":"IQVIA Ltd  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Despres","sequence":"additional","affiliation":[{"name":"IQVIA Ltd  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence Sophie","family":"Jouaville","sequence":"additional","affiliation":[{"name":"IQVIA Ltd  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Morin","sequence":"additional","affiliation":[{"name":"Inserm U1018, High\u2010Dimensional Biostatistics for Drug Safety and Genomics, CESP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2191-1773","authenticated-orcid":false,"given":"Ingrid","family":"Schubert","sequence":"additional","affiliation":[{"name":"PMV Research Group Faculty of Medicine and University Hospital of Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se\u00e1n","family":"MacBride\u2010Stewart","sequence":"additional","affiliation":[{"name":"Pharmacy Services NHS Greater Glasgow and Clyde  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Elseviers","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, University of Ghent, Ghent and Centre for Research and Innovation in Care (CRIC) University of Antwerp  Antwerp Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Nasuti","sequence":"additional","affiliation":[{"name":"IQVIA Ltd  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Taxis","sequence":"additional","affiliation":[{"name":"PharmacoTherapy, Epidemiology and Economics University of Groningen  Groningen Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Population structure and ageing\u2014statistics explained","author":"Eurostat"},{"issue":"57","key":"e_1_2_10_3_1","first-page":"729","article-title":"Association between polypharmacy and death: a systematic review and meta\u2010analysis","volume":"2017","author":"Leelakanok N","year":"2003","journal-title":"J Am Pharm Assoc"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(12)60240\u20102"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2018.06.018"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41999\u2010021\u201000479\u20103"},{"key":"e_1_2_10_7_1","first-page":"5","article-title":"Polypharmacy and inappropriate drug use among older people\u2014a systematic review","author":"Elmst\u00e5hl S","year":"2013","journal-title":"Healthy Aging Clin Care Elder"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620933741"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18073580"},{"key":"e_1_2_10_10_1","volume-title":"Polypharmacy management by 2030: a patient safety challenge","author":"Mair A","year":"2017"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877\u2010017\u20100621\u20102"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40267\u2010016\u20100299\u20100"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13095"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2019.10.022"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010015\u20101954\u20104"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010016\u20102047\u20108"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1546841"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.18632\/aging.104018"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916\u2010018\u20101078\u20107"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.13331"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afx147"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3429"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/20420986211030371"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2021.05.003"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098617715381"},{"key":"e_1_2_10_26_1","first-page":"8","article-title":"Do proton pump inhibitors increase mortality? A systematic review and in\u2010depth analysis of the evidence","author":"Ben\u2010Eltriki M","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266\u2010021\u201000893\u2010z"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118949740"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266\u2010018\u20100521\u2010y"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glr233"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.624888"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afw218"},{"key":"e_1_2_10_33_1","first-page":"630","article-title":"Good practice guidelines for designing, conducting, analyzing and reporting cross\u2010national comparison drug utilization studies","volume":"25","author":"Santa\u2010Ana\u2010Tellez Y","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_10_34_1","volume-title":"Coded clinical terms","author":"READ"},{"key":"e_1_2_10_35_1","volume-title":"ATC\/DDD index","author":"WHOCC"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"e_1_2_10_37_1","volume-title":"European Drug Utilization Research Network (EuroDURG)"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620933741"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010017\u20102276\u20105"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2016.0627"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1585"},{"key":"e_1_2_10_42_1","volume-title":"Detail","author":"AWMF"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40520\u2010022\u201002094\u2010z"},{"key":"e_1_2_10_44_1","first-page":"21","article-title":"Factors influencing trends in opioid prescribing for older people: a scoping review","author":"Mikelyte R","year":"2020","journal-title":"Prim Health Care Res Dev"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266\u2010017\u20100442\u20101"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11920\u2010016\u20100727\u20109"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz196"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14184"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4079"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.16113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T04:08:38Z","timestamp":1724904518000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.16113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/bcp.16113"],"URL":"https:\/\/doi.org\/10.1111\/bcp.16113","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]}}}